Blisibimod Withdrawn Phase 3 Trials for IgA Nephropathy (IgAN) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02052219BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy